Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Parkinson's DiseaseGait Impairment
Interventions
DRUG

Methylphenidate (MPD)

Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.

DRUG

Placebo

Participants will be given placebo instead of active MPD.

Trial Locations (1)

45219

University Neurology-Movement Disorders Clinic, Cincinnati

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

University of Cincinnati

OTHER

NCT00526630 - Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease | Biotech Hunter | Biotech Hunter